Zynex Bankruptcy Fallout: Securities Class Action Launched Over Fraud Scheme

Zynex, Inc. ($ZYXI / $ZYXIQ) is now facing a securities class action lawsuit following a dramatic collapse rooted in allegations of systematic overbilling and oversupplying that defrauded both government and private healthcare payors. The legal action, brought by the prominent securities firm Hagens Berman, comes after federal authorities indicted the company's former leadership and Tricare—Zynex's largest payor—suspended payments worth $85 million in early 2025. The company subsequently filed for Chapter 11 bankruptcy and was delisted from Nasdaq, leaving shareholders with near-total losses on their investments.

The Fraud Allegations and Leadership Indictments

At the center of the legal turmoil are former CEO Thomas Sandgaard and former COO Anna Lucsok, both of whom were indicted for healthcare and securities fraud. The allegations paint a picture of a company engaged in a deliberate scheme to overbill and oversupply medical devices and services to government and private payors over an extended period. This systematic fraud not only deceived payers but also misled investors about the company's financial health and operational practices.

The magnitude of the misconduct became apparent when Tricare, the healthcare program serving active-duty military members, retirees, and their families, abruptly suspended payments in early 2025. The suspension resulted in an $85 million forfeiture, a crushing blow for a company that relied heavily on this single payor relationship. The loss of Tricare payments essentially severed a critical revenue lifeline, accelerating the company's financial deterioration and triggering the cascade of bankruptcies and delistings that followed.

Market Context: Healthcare Fraud and Industry Oversight

Zynex's collapse reflects broader vulnerabilities in healthcare billing oversight and the significant risks posed by concentrated payor relationships. The company operates in the medical device and rehabilitation equipment sector, a space that has faced increasing scrutiny from federal authorities in recent years.

Key factors that contextualize this crisis include:

• Payor concentration risk: Tricare represented such a dominant portion of Zynex's revenue that its suspension was existential
• Healthcare fraud enforcement: Federal authorities have escalated investigations into billing practices across the medical device sector
• Nasdaq delisting consequences: The removal from the exchange has made the stock illiquid and essentially worthless for retail investors
• Bankruptcy timeline: The rapid progression from payment suspension to Chapter 11 filing suggests minimal financial reserves or operational flexibility

The healthcare device industry has seen heightened regulatory scrutiny over billing practices, particularly for durable medical equipment and rehabilitation services. Companies with heavy reliance on government contracts face particular vulnerability, as federal payors possess the authority to investigate, suspend, and terminate payments swiftly when fraud is suspected.

Zynex's situation stands as a cautionary tale about governance failures and the importance of diversified payor relationships. Unlike larger, more diversified healthcare companies, Zynex lacked the financial cushion to weather the loss of its primary revenue source.

Investor Implications: Total Loss and Legal Recourse

For Zynex shareholders, the impact has been catastrophic. The Nasdaq delisting combined with Chapter 11 bankruptcy means that shares have become nearly worthless, with equity holders typically receiving nothing in a bankruptcy reorganization after creditors are paid. The stock's removal from major exchanges has also eliminated trading liquidity, leaving investors with unmarketable securities.

The securities class action lawsuit, with a lead plaintiff deadline of April 21, 2026, represents one of the limited avenues for investor recovery. Class action settlements in cases involving fraud and bankruptcy can provide some compensation to affected shareholders, though recovery rates are typically modest. The involvement of Hagens Berman, a firm with a strong track record in securities litigation, suggests the case has legal merit, but success is far from guaranteed.

Key considerations for affected investors:

• Near-total shareholder loss: Equity is typically wiped out in bankruptcy filings
• Class action opportunity: The lawsuit deadline of April 21, 2026, provides a window for shareholders to join and potentially recover a portion of losses
• Limited recovery prospects: Even successful class actions typically result in settlements representing cents on the dollar of original investment
• Nasdaq delisting impacts: The stock is no longer traded on major exchanges, making shares illiquid

This case also underscores broader governance and audit failures. Questions likely surround how Tricare and private insurers failed to detect the overbilling scheme earlier, as well as how the company's auditors and board of directors allowed such misconduct to persist.

Forward Outlook

Zynex's collapse will likely prompt increased scrutiny of medical device company billing practices and governance structures across the industry. Investors in healthcare-related stocks should pay particular attention to payor concentration, audit quality, and the robustness of internal controls. The case demonstrates that even companies operating in growing healthcare sectors remain vulnerable to catastrophic failure when fraud, governance failures, and concentrated revenue relationships converge.

For shareholders affected by the Zynex collapse, the securities class action represents an important but limited opportunity for recovery. Those who held shares during the relevant period should review the claim procedures and deadlines associated with the litigation. While the April 21, 2026, lead plaintiff deadline marks a critical juncture, affected investors should act promptly to preserve their legal rights and ensure their participation in any eventual settlement.